Sagimet Biosciences Inc.
NASDAQTotal Valuation
Sagimet Biosciences Inc. carries a market capitalization of 321.11M, placing it among publicly traded companies globally. Its enterprise value stands at 239.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 321.11M |
| Enterprise Value | 239.39M |
Share Statistics
Sagimet Biosciences Inc. currently has 61.78M shares outstanding.
| Shares Outstanding | 61.78M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.86 |
| P/TBV Ratio | 1.86 |
| P/FCF Ratio | -6.98 |
| P/OCF Ratio | -6.98 |
Financial Position
Sagimet Biosciences Inc. maintains a current ratio of 45.02, meaning it holds 45.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 45.02 |
| Quick Ratio | 44.31 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -24.37 |
| Return on Assets (ROA) | -23.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Sagimet Biosciences Inc.'s stock has gained approximately 25.86845% over the past 52 weeks. The 50-day moving average sits at 9.93, while the 200-day moving average is 7.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | 25.86845% |
| 50-Day Moving Average | 9.93 |
| 200-Day Moving Average | 7.31 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -52.63M, while operating income came in at -52.63M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -52.63M |
| Pretax Income | -47.08M |
| Net Income | -47.08M |
| EBITDA | -52.63M |
| EBIT | -52.63M |
| Earnings Per Share (EPS) | -1.25 |
Balance Sheet
Sagimet Biosciences Inc. holds 240.13M in cash and equivalents against 1.94M in total debt, resulting in a net debt position of -165.90M. Total book value stands at 256.16M, with working capital of 238.57M providing operational flexibility.
| Cash & Cash Equivalents | 240.13M |
| Total Debt | 1.94M |
| Net Debt | -165.90M |
| Equity (Book Value) | 256.16M |
| Book Value Per Share | 4.15 |
| Working Capital | 238.57M |
Cash Flow
Sagimet Biosciences Inc. produced -41.72M in operating cash flow over the past twelve months.
| Operating Cash Flow | -41.72M |
| Capital Expenditures | N/A |
| Free Cash Flow | -41.72M |
| FCF Per Share | -1.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.06 |
| FCF Yield | -14.33 |
Scores
Sagimet Biosciences Inc. posts an Altman Z-Score of 37.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 37.84 |